IncyteINCY
NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation
Biopharma focused on oncology and inflammation (Jakafi, Opzelura).
Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.
Key metrics
Market cap
$23.5B
Price
$116.61
Today
−1.6%
Return YTD
+20.0%
Return 1Y
+72.5%
P/E
16.4
P/S
4.4
P/B
4.2
Data as of 2026-07-10 · updates daily after U.S. close
Theme exposure
In the value chain
Products & services
- Jakafi (myelofibrosis)
- Opzelura (dermatology)
- Oncology pipeline
Competitors
Risks
- Jakafi concentration
- Patent expiry
Same segment: Biotech & innovation
See where Incyte sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →